# NT-proBNP bij systematische screening op atriumfibrilleren

*geplaatst 2017-08-01 · Atriumfibrilleren · Heart (British Cardiac Society) · doi 10.1136/heartjnl-2016-310236 · https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/*

Studie naar het gebruik van NT-proBNP als screeningsinstrument voor detectie van atriumfibrilleren in een populatiescreeningssetting. Biomarkergestuurde AF-opsporing.

## English: N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation.

This study evaluated NT-proBNP as a pre-screening tool for systematic AF detection in the community, showing that elevated natriuretic peptide levels can efficiently identify individuals most likely to have undiagnosed arrhythmia.

## Abstract (original, from the publication)

OBJECTIVE: Screening for atrial fibrillation (AF) in individuals aged 65 and above is recommended by the European Society of Cardiology. Increased levels of the biomarker N-terminal pro B-type natriuretic peptide (NT-proBNP) has in cohort studies been associated with incident AF.The aim of this study was to assess whether NT-proBNP could be useful for AF detection in systematic screening. METHODS: The Strokestop study entailed 7173 Swedish residents aged 75/76 that were screened for AF using twice daily intermittent ECG recordings during 2 weeks. In a substudy of 886 participants, the last 815 consecutive participants and 71 individuals with newly detected AF, levels of NT-proBNP were determined. RESULTS: Participants with newly detected AF (n=96) had a median NT-proBNP of 330 ng/L (IQR 121;634). In individuals without AF (n=742), median NT-proBNP was 171 ng/L (IQR 95;283), p<0.001. The CHA2DS2-VASc parameters did not differ significantly between individuals with newly detected AF and without AF nor between newly detected AF in the NT-proBNP cohort compared with the cohort where NT-proBNP was not assessed. Using an NT-proBNP cut-off of ≥125 ng/L in a non-acute setting yielded a negative predictive value of 92%, meaning that 35% fewer participants would need to be screened when applied to systematic AF screening. Adding weight to NT-proBNP further reduced participants needed to be screened with a preserved sensitivity. CONCLUSIONS: NT-proBNP was increased in individuals with newly detected AF. Prospective studies could clarify if NT-proBNP can be used to correctly select individuals that benefit most from AF screening. CLINICAL TRIALS: ClinicalTrials.gov. Identifier: NCT01593553.

Auteurs: Emma Svennberg, Peter Henriksson, Johan Engdahl, Ziad Hijazi, Faris Al-Khalili, Leif Friberg, Viveka Frykman

---
Bron: Heart (British Cardiac Society), https://doi.org/10.1136/heartjnl-2016-310236. Bijgewerkt 2026-07-03T18:38:34Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.